Express Pharma

JUNE 20, 2023

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Reductionist systems, such as genetically identical inbred mice, have long been the choice for immunology research, which focuses on studying the cells, tissues, and organs that make up the immune system.

Immunity 102

Immunity Immunization Vaccines Hospitals 102

Express Pharma

AUGUST 27, 2024

Indian Immunologicals Limited (IIL) has announced the development of a live-attenuated, needle-free intranasal booster vaccine against SARS-CoV-2. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over.

Vaccines 89

Vaccines Immunity Immunization Communication 89

STAT

OCTOBER 8, 2024

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. A group of doctors and medical practices claimed they overpaid for the vaccine, which was the only mumps shot in the U.S. We trust you have your own hectic agendas. ” A U.S.

Compounding 208

Compounding Compounding Pharmacies Vaccines Immunity 208

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunity Immunization 110

Express Pharma

SEPTEMBER 26, 2023

Indian Institute of Technology Mandi researchers, led by Dr Amit Prasad, Associate Professor, School of Biosciences and Bioengineering, has made strides in the development of vaccines against the pork tapeworm (T. Traditionally, tapeworm vaccines have been developed using products or antigens derived from tapeworm eggs or larvae.

Vaccines 102

Vaccines Immunity Immunization Hospitals 102

STAT

FEBRUARY 22, 2023

This year’s flu shot generated relatively robust levels of protection, new data show, with the vaccine’s effectiveness ranging between about 45% and 55%, depending on the age group and the metric studied, such as whether there was protection against any infection or infection that was severe enough to require hospitalization.

Immunization 246

Immunization Immunity Hospitals Vaccines 246

European Pharmaceutical Review

SEPTEMBER 20, 2023

Results of a Phase I/II study has revealed that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine induces a robust, broadly cross-reactive, and durable immune response in adults. Participants received one booster dose on Day 1 of either the ARCT-021, ARCT-154, or ARCT-165 vaccines.

Vaccines 98

Vaccines Immunity Immunization 98

World Pharma News

OCTOBER 9, 2023

NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Pfizer Inc. Data from 45 abstracts will highlight the advances Pfizer is making in helping prevent and treat certain infectious diseases, particularly respiratory illnesses.

Vaccines 86

Vaccines Immunity Immunization 86

pharmaphorum

JULY 26, 2021

While there are plenty of tests already available that can give a yes/no reading of whether antibodies are present, the Chembio test measures the level of antibodies as well, so can tell whether a patient is likely to be protected against the coronavirus. The post Rapid COVID immune status test launched in UK, Ireland appeared first on.

Immunity 137

Immunity Immunization Vaccines 137

Pharmafile

APRIL 3, 2023

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. read more

Vaccines 72

Vaccines Immunity Immunization 72

ALiEM - Pharm Pearls

OCTOBER 25, 2024

A 64-year-old male with a history of bipolar 1 disorder, PTSD, anxiety, depression, obsessive-compulsive disorder, GERD, and HTN presented to the ED with the chief complaint of foreign body and self-injury. Numerous linear metallic foreign bodies are present throughout the right forearm; several new foreign bodies are noted.

Vaccines 177

Vaccines Immunity Immunization 177

European Pharmaceutical Review

APRIL 25, 2023

The R21/Matrix-M malaria vaccine, developed by the University of Oxford , has been approved for use in Ghana (13 April 2023) and was authorised for use in Nigeria on 17 April. How does the R21/Matrix-M vaccine work? This technology has been used successfully in Novavax’s COVID-19 vaccine.

Vaccines 111

Vaccines Immunity Immunization 111

Pharmafile

OCTOBER 25, 2023

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory syncytial virus (RSV) vaccine, adjuvanted, in adults aged 50 to 59 including those at an increased risk of RSV lower respiratory tract disease (LRTD) due to underlying conditions.

Vaccines 59

Vaccines Immunization Immunity 59

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works.

Vaccines 135

Vaccines Health and Personal Care Stores Immunity Immunization 135

Pharmaceutical Business Review

SEPTEMBER 10, 2024

Under the terms of the agreement, KM Biologics will carry out the development, manufacturing, and commercialisation of Osivax’s vaccine. In June last year, Osivax began a Phase IIa trial administering the first dose of its vaccine candidate OVX836 to a participant in Australia.

Vaccines 59

Vaccines Immunity Immunization 59

European Pharmaceutical Review

MAY 12, 2023

A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). Can an mRNA vaccine stimulate T cell response?

Vaccines 98

Vaccines Immunity Immunization Chemotherapy 98

Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunity 52

Immunity Immunization Vaccines 52

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines 138

Vaccines Immunity Immunization 138

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.

Vaccines 105

Vaccines Immunity Immunization 105

Pharmacy Joe

SEPTEMBER 23, 2021

In this episode, I’ll discuss a possible syndrome that might herald vaccine-induced immune thrombotic thrombocytopenia. Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ? All 11 patients presented with severe headache 5 to 18 days after adenovirus vector vaccination.

Immunity 40

Immunity Immunization Vaccines Inpatient 40

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . The novel vaccine, which is based on mosaic?8 How the novel coronavirus vaccine works. The novel vaccine?is

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 92

Vaccines Immunity Immunization 92

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

AUGUST 3, 2022

The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses, such as influenza and coronaviruses, on global health. Current vaccine strategies and their limitations. The adaptive immune response to a natural infection.

Vaccines 95

Vaccines Immunity Immunization 95

pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.

Vaccines 133

Vaccines Adverse Reactions Immunity Immunization 133

European Pharmaceutical Review

OCTOBER 21, 2022

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. An interim analysis conducted over more than four years of long-term follow-up (LTFU) showed vaccine efficacy was 81.6

Vaccines 105

Vaccines Immunity Immunization 105

Express Pharma

OCTOBER 17, 2023

Cellipoint Bioservices entered an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine. The FDA subsequently granted the vaccine a Fast Track Designation for the indication. months longer than placebo. months longer than placebo.

Vaccines 93

Vaccines Immunity Immunization 93

Pharmaceutical Business Review

APRIL 3, 2024

The Centers for Disease Control and Prevention (CDC) had provided interim guidance for the vaccine’s pre- and post-exposure use during the outbreak for people at risk. The CDC estimates that two million individuals in the US are eligible for the mpox vaccination.

Vaccines 52

Vaccines Physician Offices Immunity Immunization 52

pharmaphorum

OCTOBER 18, 2021

An FDA advisory committee voted unanimously in favour of a booster dose of Johnson & Johnson’s one-shot COVID-19 vaccine on Friday, as panellists suggested it should have been used as a two-dose regimen from the start. All told, 15 million people in the US have been vaccinated with Ad26.COV2.S,

Vaccines 92

Vaccines Immunity Immunization 92

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunity Immunization 119

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series.

Vaccines 96

Vaccines Immunity Immunization 96

pharmaphorum

AUGUST 25, 2022

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Podbean. .

Vaccines 52

Vaccines Immunity Immunization 52

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccines 59

Vaccines Immunity Immunization 59

Pharmaceutical Technology

AUGUST 15, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna ’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above. It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1

Vaccines 85

Vaccines Immunity Immunization 85

European Pharmaceutical Review

AUGUST 30, 2022

Pfizer has announced positive top-line data from a Phase III clinical trial (NCT05035212) investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. In more severe disease with primary endpoint of LRTI-RSV defined by three or more symptoms, vaccine efficacy of 85.7

Vaccines 98

Vaccines Immunity Immunization 98

Express Pharma

JUNE 9, 2024

GSK announced that the US FDA has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 to 59 years of age who are at increased risk. This antigen is combined with GSK’s proprietary AS01E adjuvant.

Vaccines 104

Vaccines Immunity Immunization Diabetes 104